NESS ZIONA, Israel, Nov. 10, 2008 (GLOBE NEWSWIRE) -- Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has signed a long-term supply agreement with a multi-national company for the raw material required to manufacture AAT (alpha-1-antitrypsin), Kamada's flagship product, which is administered intravenously (IV) or by inhalation.
